TVTX Travere Therapeutics, Inc.
$51.10
Travere Therapeutics, Inc. (TVTX) Earnings News
Earnings press releases, previews and reviews for Travere Therapeutics, Inc. (TVTX), newest first. Our most recent is review: Travere's FILSPARI Tops $200 Million as Revenue Beats, but a Deal Charge Drives an EPS Miss and Softer New-Patient Starts Cloud the Ramp.
Monday
November 2, 2026
7:35 PM ET
Travere's FILSPARI Tops $200 Million as Revenue Beats, but a Deal Charge Drives an EPS Miss and Softer New-Patient Starts Cloud the Ramp
Earnings Whispers · Review
Monday
November 2, 2026
4:01 PM ET
Travere Therapeutics Reports Third Quarter 2026 Financial Results
Monday
October 26, 2026
11:37 PM ET
Travere's FSGS Launch Faces Its Durability Test as Stock Slides Toward Post-Earnings Lows
Earnings Whispers · Preview
Monday
October 26, 2026
4:30 PM ET
Travere Therapeutics to Report Third Quarter 2026 Financial Results
Tuesday
August 4, 2026
4:01 PM ET
Travere Therapeutics Reports Second Quarter 2026 Financial Results
Tuesday
July 28, 2026
4:30 PM ET
Travere Therapeutics to Report Second Quarter 2026 Financial Results